History repeats itself: the family medication history and pharmacogenomics.

abstract：AIM:GLP-1 plays a key role in glucose metabolism and influences antipsychotic-induced weight gain (AIWG). Our study is the first to investigate the encoding gene, GCG, and the GLP-1 receptor gene, GLP1R, and association with AIWG. MATERIALS & METHODS:In 216 schizophrenic patients treated with antipsychotics for up to ...

journal_title：Pharmacogenomics

authors： Brandl EJ,Tiwari AK,Chowdhury NI,Zai CC,Lieberman JA,Meltzer HY,Kennedy JL,Müller DJ

更新日期：2014-03-01 00:00:00

abstract：AIM:To determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. MATERIALS & METHODS:We investigated two Turkish warfarin-treated cohorts: patients with no history of...

journal_title：Pharmacogenomics

authors： Karaca S,Bozkurt NC,Cesuroglu T,Karaca M,Bozkurt M,Eskioglu E,Polimanti R

更新日期：2015-01-01 00:00:00

abstract：:Quantitative trait analysis (QTA) can be used to test whether the expression of a particular gene significantly correlates with some ordinal variable. To limit the number of false discoveries in the gene list, a multivariate permutation test can also be performed. The purpose of this study is to identify peripheral bl...

journal_title：Pharmacogenomics

authors： Whistler T,Taylor R,Craddock RC,Broderick G,Klimas N,Unger ER

更新日期：2006-04-01 00:00:00

abstract：:Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to arylhydrazines and to arylamine drugs and carcinogens or to their N-hydroxylated metabolites. NAT plays an important role in detoxification and metabolic activation of xenobiotics and was first identified as the enzyme re...

journal_title：Pharmacogenomics

authors： Pompeo F,Brooke E,Kawamura A,Mushtaq A,Sim E

更新日期：2002-01-01 00:00:00

abstract：AIM:To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. METHODS:A comprehensive search was performed up to June 2013. The methodological quality of...

journal_title：Pharmacogenomics

authors： Cargnin S,Jommi C,Canonico PL,Genazzani AA,Terrazzino S

更新日期：2014-05-01 00:00:00

abstract：:For the last 40 years, 5-fluorouracil (5-FU) has remained the treatment of choice in both the adjuvant and advanced treatment of colorectal cancer (CRC). However, 5-FU monotherapy produces response rates of only 10-20% in the advanced setting. 5-FU has been combined with newer agents, such as oxaliplatin and irinoteca...

journal_title：Pharmacogenomics

authors： Allen WL,Johnston PG

更新日期：2005-09-01 00:00:00

abstract：:Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. Approximately 5% of patients treated with abacavir develop a hypersensitivity reaction that requires discontinuation of the drug. In an initial pharmacogenetic study conducted in a predominantly White male population, multiple markers in the h...

journal_title：Pharmacogenomics

authors： Hughes AR,Mosteller M,Bansal AT,Davies K,Haneline SA,Lai EH,Nangle K,Scott T,Spreen WR,Warren LL,Roses AD,CNA30027 Study Team.,CNA30032 Study Team.

更新日期：2004-03-01 00:00:00

abstract：:The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin int...

journal_title：Pharmacogenomics

authors： V Willrich MA,Kaleta EJ,Bryant SC,Spears GM,Train LJ,Peterson SE,Lennon VA,Kopecky SL,Baudhuin LM

更新日期：2018-01-01 00:00:00

abstract：:The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADRbeta2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ...

journal_title：Pharmacogenomics

authors： Hawkins GA,Weiss ST,Bleecker ER

更新日期：2008-03-01 00:00:00

abstract：:Cost-effectiveness analysis is a widely used tool to assess the value of healthcare interventions. Our objective was to conduct a systematic review of the literature on the cost effectiveness of pharmacogenomic interventions. We found 11 studies that met our inclusion criteria. The most commonly examined disease was d...

journal_title：Pharmacogenomics

authors： Phillips KA,Van Bebber SL

更新日期：2004-12-01 00:00:00

abstract：:Second-generation antipsychotics can greatly improve symptoms of psychosis-spectrum disorders. Unfortunately, these drugs are associated with weight gain, which increases a patient's risk for developing chronic diseases including Type 2 diabetes, cardiovascular diseases or other obesity-related complications. There ar...

journal_title：Pharmacogenomics

authors： Lee AK,Bishop JR

更新日期：2011-07-01 00:00:00

abstract：:CYP2D6*84 was first described in a Black South African subject, however, its function remains unknown. Astrolabe, a probabilistic scoring tool developed in our laboratory to call genotypes from whole genome sequence, identified CYP2D6*84 in a trio. The father presented with intermediate metabolism when challenged with...

journal_title：Pharmacogenomics

authors： Gaedigk A,Twist GP,Farrow EG,Lowry JA,Soden SE,Miller NA

更新日期：2017-04-01 00:00:00

abstract：OBJECTIVES:The aim of this study was to investigate whether the polymorphisms in the NR1I2 and ABCB1 genes were associated with epilepsy treatment responses. METHODS & RESULTS:NR1I2and ABCB1 polymorphisms were genotyped in 114 drug-resistant epileptic patients, 213 seizure-free patients and 287 normal controls. Highly...

journal_title：Pharmacogenomics

authors： Hung CC,Jen Tai J,Kao PJ,Lin MS,Liou HH

更新日期：2007-09-01 00:00:00

abstract：AIM:The present study explored the integrative effect of genes encoding methadone pharmacokinetic and pharmacodynamic pathways on methadone maintenance doses in Han Chinese Patients. MATERIALS & METHODS:Genomic DNA was extracted from 321 opioid-dependent patients and 202 healthy controls, and realtime-PCR and PCR-RFLP...

journal_title：Pharmacogenomics

authors： Hung CC,Chiou MH,Huang BH,Hsieh YW,Hsieh TJ,Huang CL,Lane HY

更新日期：2011-11-01 00:00:00

abstract：:Recent research highlighted the large extent of rare variants in pharmacogenes and, on this basis, it was estimated that rare variants account for 30-40% of the functional variability in pharmacogenes. It has been proposed that comprehensive next-generation sequencing (NGS)-based sequencing of pharmacogenes could soon...

journal_title：Pharmacogenomics

authors： Lauschke VM,Ingelman-Sundberg M

更新日期：2016-06-01 00:00:00

abstract：:Individuals with neuropsychiatric diseases have epigenetic programming disturbances, both in the brain, which is the primary affected organ, and in secondary tissues. Epigenetic modulations are molecular modifications made to DNA, RNA and proteins that fine-tune genotype into phenotype and do not include DNA base chan...

journal_title：Pharmacogenomics

authors： Abdolmaleky HM,Zhou JR,Thiagalingam S,Smith CL

更新日期：2008-12-01 00:00:00

abstract：:The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for ab...

journal_title：Pharmacogenomics

authors： van Schie RM,Wadelius MI,Kamali F,Daly AK,Manolopoulos VG,de Boer A,Barallon R,Verhoef TI,Kirchheiner J,Haschke-Becher E,Briz M,Rosendaal FR,Redekop WK,Pirmohamed M,Maitland van der Zee AH

更新日期：2009-10-01 00:00:00

abstract：AIM:The activity of several key enzymes involved in the metabolism of many drugs is subject to change closely related to the age of patients. This possibility must also be considered in the case of tacrolimus, the most important calcineurins inhibitor, which is widely used in pediatric kidney transplantation. As well a...

journal_title：Pharmacogenomics

authors： Ferraresso M,Turolo S,Belingheri M,Tirelli AS,Cortinovis I,Milani S,Edefonti A,Ghio L

更新日期：2015-01-01 00:00:00

abstract：AIM:To investigate the pharmacokinetics of voriconazole when administered to HIV-positive patients receiving treatment with atazanavir-containing therapies according to CYP2C19 genotype. MATERIALS & METHODS:We describe four HIV-positive patients with pulmonary aspergillosis treated with voriconazole and atazanavir-bas...

journal_title：Pharmacogenomics

authors： Calcagno A,Baietto L,Pagani N,Simiele M,Audagnotto S,D'Avolio A,De Rosa FG,Di Perri G,Bonora S

更新日期：2014-07-01 00:00:00

abstract：INTRODUCTION:Methotrexate (MTX), widely used in the treatment of rheumatoid arthritis (RA), inhibits dihydrofolate reductase and folate-dependent enzymes. Methylenetetrahydrofolate reductase (MTHFR) is involved in folate metabolism and has been shown to be polymorphic, affecting the enzyme activity. METHODS:To examine...

journal_title：Pharmacogenomics

authors： Kurzawski M,Pawlik A,Safranow K,Herczynska M,Drozdzik M

更新日期：2007-11-01 00:00:00

abstract：:Psoriasis vulgaris is one of the most prevalent T cell-mediated inflammatory diseases in humans. It is multifactorial in origin and shows polygenic inheritance. Systemic immunosuppressive therapies play an important role in management of severe disease cases but are associated with variable response and toxicity. With...

journal_title：Pharmacogenomics

authors： Ameen M

更新日期：2003-05-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability...

journal_title：Pharmacogenomics

authors： Megías-Vericat JE,Montesinos P,Herrero MJ,Bosó V,Martínez-Cuadrón D,Poveda JL,Sanz MÁ,Aliño SF

更新日期：2016-07-01 00:00:00

abstract：:This narrative review describes implementation, current status and perspectives of a pharmacogenomic (PGx) program at the Brazilian National Cancer Institute (INCA), targeting the cancer chemotherapeutic drugs - fluoropyrimidines, irinotecan and thiopurines. This initiative, designed as a research project, was support...

journal_title：Pharmacogenomics

authors： Suarez-Kurtz G,Kovaleski G,Elias AB,Motta V,Wolch K,Emerenciano M,Mansur MB,Palladino AM,Accioly MT,Ferreira M,Gonçalves AA,de Melo AC

更新日期：2020-06-01 00:00:00

abstract：:Choline phospholipid metabolism is altered in a wide variety of cancers. The choline metabolite profile of tumors and cancer cells is characterized by an elevation of phosphocholine and total choline-containing compounds. Noninvasive magnetic resonance spectroscopy can be used to detect this elevation as an endogenous...

journal_title：Pharmacogenomics

authors： Glunde K,Serkova NJ

更新日期：2006-10-01 00:00:00

abstract：:Currently, there is sufficient evidence for the use of pharmacogenetic information to optimize medication prescribing, but why has this information not been integrated into the drug prescribing process to improve patient care? A discussion about the major contributing factors that have limited the use of pharmacogenet...

journal_title：Pharmacogenomics

authors： Wiltshire T,Dong OM

更新日期：2018-04-01 00:00:00

abstract：AIM:We aimed to understand consent practices for pharmacogenetic (PGx) testing. METHODS:We conducted a literature review and analysis of consent forms from clinical laboratories offering PGx testing. RESULTS:Our review of the literature shows a lack of consensus about the need for and type of informed consent for PGx...

journal_title：Pharmacogenomics

authors： Haga SB,Mills R

更新日期：2016-09-01 00:00:00

abstract：AIMS:The identification of predictive markers of response to chemoradiotherapy treatment remains a promising approach for patient management in order to obtain the best response with minor side effects. Initially, we investigated whether the analysis of several markers previously studied and others not yet evaluated co...

journal_title：Pharmacogenomics

authors： Balboa E,Duran G,Lamas MJ,Gomez-Caamaño A,Celeiro-Muñoz C,Lopez R,Carracedo A,Barros F

更新日期：2010-06-01 00:00:00

abstract：:Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since 2009, with the discovery of 49 SNPs associated with disease susceptibility and 46 with impact in the clinical outcome of patients (p < 5.00 × 10-...

journal_title：Pharmacogenomics

authors： Pinto R,Assis J,Nogueira A,Pereira C,Pereira D,Medeiros R

更新日期：2017-11-01 00:00:00

abstract：:Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...

journal_title：Pharmacogenomics

authors： Schumacher-Schuh AF,Rieder CR,Hutz MH

更新日期：2014-06-01 00:00:00

abstract：:Recent years have seen great advances in our understanding of genetic contributors to drug response. Drug discovery and development around targeted genetic (somatic) mutations has led to a number of new drugs with genetic indications, particularly for the treatment of cancers. Our knowledge of genetic contributors to ...

journal_title：Pharmacogenomics

authors： Johnson JA

更新日期：2013-05-01 00:00:00